The size of the European Injectable Drug Delivery Market was calculated at USD 1123 million in 2020. It is further estimated to be growing at a CAGR of 11.90%, to reach USD 1970 million by 2025.
Injectable drug delivery is characterized as introducing a drug or drugs in the patient by utilizing a delivery device. Injectables permit the transport of drug in the fluid form directly into the body.
The major factors which drive the market growth are increasing demand and technological advances for devices. The major limitations are infections and injuries due to Injectables and regulatory framework issues. The injectable medication delivery market is led by North America and is trailed by Europe.
However, North American lags behind the European injectable market in self-infusion devices because of the low penetration rate of pen injectors in the U.S.
This research report on the European Injectable Drug Delivery Market has been segmented and sub-segmented into the following categories:
By Device Type:
By Formulation:
By Therapeutic use:
By End User:
By Country:
Notable companies operating in the European Injectable drug delivery market profiled in the report are Antares Pharmaceuticals Ltd, Baxter International, Becton Dickinson Company, Elcam Medical, Eli Lily and Company, Unilife Corporation, and West Pharmaceutical Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Device Type
5.1.1 Introduction
5.1.2 Self-injection Devices
5.1.3 Conventional Devices
5.1.4 Y-o-Y Growth Analysis, By Device Type
5.1.5 Market Attractiveness Analysis, By Device Type
5.1.6 Market Share Analysis, By Device Type
5.2 Formulation
5.2.1 Introduction
5.2.2 Conventional Drug Delivery
5.2.3 Novel Drug Delivery
5.2.4 Y-o-Y Growth Analysis, By Formulation
5.2.5 Market Attractiveness Analysis, By Formulation
5.2.6 Market Share Analysis, By Formulation
5.3 Therapeutic Use
5.3.1 Introduction
5.3.2 Autoimmune Disorders
5.3.3 Hormonal Disorders
5.3.4 Oncology
5.3.5 Y-o-Y Growth Analysis, By Therapeutic Use
5.3.6 Market Attractiveness Analysis, By Therapeutic Use
5.3.7 Market Share Analysis, By Therapeutic Use
5.4 End-user
5.4.1 Introduction
5.4.2 Hospitals
5.4.3 Homecare Settings
5.4.4 Research Institutes
5.4.5 Clinical Laboratories
5.4.6 Other
5.4.7 Y-o-Y Growth Analysis, By End-user
5.4.8 Market Attractiveness Analysis, By End-user
5.4.9 Market Share Analysis, By End-user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Device Type
6.1.3.3 By Formulation
6.1.3.4 By Therapeutic Use
6.1.3.5 By End-user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Device Type
6.1.4.3 By Formulation
6.1.4.4 By Therapeutic Use
6.1.4.5 By End-user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Device Type
6.1.5.3 By Formulation
6.1.5.4 By Therapeutic Use
6.1.5.5 By End-user
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Alkermes Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bend Research
8.3 BIND Biosciences Inc.
8.4 Endocyte
8.5 Genentech Inc.
8.6 MicroCHIPS Inc.
8.7 Pearl Therapeutics Inc.
8.8 Polymer Factory
8.9 Presage Bioscience
8.10 QLT Inc.
8.11 UCB Group.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
